Coronavirus: AstraZeneca and Oxford resume COVID-19 vaccine trial

Tuesday, 15 Sep, 2020

Earlier, the China National Biotech Group (CNBG) and Synovac Biotech Limited claimed that four more countries including Serbia and Pakistan have approved the final stage trials of the Covid vaccine made in China.

The proposed expansion would also allow the companies to enroll people as young as 16 and people with chronic, stable HIV, hepatitis C and hepatitis B, they added.

In a statement on Monday, researchers at Imperial College London and Oxford University said a trial involving 30 people would test vaccines developed by both institutions when participants inhale the droplets in their mouths, which would directly target their respiratory systems.

AstraZeneca has reaffirmed its commitment to the safety of trial participants and the highest standards of conduct in clinical trials.

American pharmaceutical company Pfizer Inc is one of the leading frontrunners in the global COVID-19 vaccine race.

Germany's BioNTech and US-based Pfizer are developing a nucleoside-modified messenger RNA vaccine candidate. The timing of clinical trial results depends on enough people in the study getting Covid-19 to make a calculation.

Rules regarding the Covid 19 vaccine
Promising Coronavirus Vaccine Resumes Trials After Brief Pause

Currently, there are 35 vaccines in human trials around the world, and eight of them are in late-stage, large clinical trials, according to the World Health Organization (WHO). Mysuru-based JSS Hospital and Medical College is among the 17 centres that have been selected in India for clinical trials of the potential vaccine.

Last week, Oxford temporarily paused its large-scale vaccination tests after one participant in the United Kingdom reported severe neurological symptoms; it was restarted on Sunday. On the India trials, SII said, "Once DCGI will give us the permission to restart the trials in India, we will resume the trials".

An AstraZeneca spokesperson previously described the decision as a "routine action which has to happen whenever there is a potentially unexplained illness" in a trial.

An AstraZeneca spokesperson confirmed the pause in vaccinations covered studies in the USA and other countries.

The vaccine had previously generated strong immune responses, and is now in phase three trials - the final step before a vaccine is approved.

Clinical trials were also paused in July when a volunteer experienced neurological issues, AstraZeneca CEO Pascal Soriot told investors from J.P. Morgan Wednesday, according to STAT.